Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AKT2
REST API REST API
Homo sapiens
AKT2 is differentially expressed in 294 experiments: 146 organism parts: bone marrow, blood, ... (144 more);, 194 disease states: normal, Burkitt's lymphoma, ... (192 more);, 91 cell types 385 cell lines 35 compound treatments and 82 other conditions.
Orthologs ENSCING00000008043 (Ciona intestinalis)   Akt2 (Mus musculus)   Akt2 (Rattus norvegicus)   AKT2 (Bos taurus)   akt2l (Danio rerio)   akt2 (Danio rerio)   Akt1 (Drosophila melanogaster)   SCH9 (Saccharomyces cerevisiae)   akt2 (Xenopus laevis)   NP_001012340.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, regulation of JNK cascade, phosphorylation, positive regulation of nitric oxide biosynthetic process, protein binding, vesicle, positive regulation of gene expression, negative regulation of apoptosis, response to osmotic stress, protein tyrosine kinase activity, insulin receptor signaling pathway, soluble fraction, protein kinase B signaling cascade, ATP binding, positive regulation of transcription from RNA polymerase II promoter, transferase activity, transferring phosphorus-containing groups, microsome, protein modification process, nucleus, regulation of cell migration, lamellipodium, nucleotide binding, kinase activity, protein serine/threonine kinase activity, nucleoplasm, signal transduction, negative regulation of caspase activity, protein kinase activity, mitochondrion, negative regulation of RNA splicing, positive regulation of peptidyl-serine phosphorylation, cellular response to insulin stimulus, fat cell differentiation, positive regulation of cell migration, cellular response to chemical stimulus, negative regulation of plasma membrane long-chain fatty acid transport, protein kinase C binding, positive regulation of glycogen biosynthetic process, insulin-responsive compartment, positive regulation of positive chemotaxis, mammary gland epithelial cell differentiation, response to insulin stimulus, positive regulation of glucose import, positive regulation of signal transduction, response to muscle activity, cellular response to hormone stimulus, positive regulation of fatty acid beta-oxidation, positive regulation of sodium ion transport, positive regulation of glucose metabolic process, protein phosphorylation, positive regulation of protein phosphorylation, regulation of cell cycle arrest, positive regulation of cell motility
InterPro Term Pkinase_C, AGC-kinase_C, Prot_kinase_cat_dom, Pleckstrin_homology, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession C9J258, Q0VAN0, A8MX96, C9JC83, C9JIJ1, C9JIF6, C9JHS6, C9K000, Q6P4H3, P31751, B4DG79, B3KP61, Q05BV0, E7EVP8, B7Z8Z9
Gene-Disease Assocation DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM
Search EB-eye ENSG00000105221
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (37 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
SNU16
2
E-GEOD-15460, E-MTAB-37
HT1080
2
E-GEOD-20089, E-MTAB-37
SNU1
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
379 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (46 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998, E-GEOD-96
BDCA3+ dendritic cell
1
1
E-TABM-34
secretory cell
1
E-GEOD-3998
pro B cell
1
E-MEXP-1403
ADC
1
1
E-GEOD-19188
macrophage; T cell
1
E-MEXP-1290
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (64 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
breast cancer
2
E-MTAB-62, E-GEOD-22544
glioblastoma
2
E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-GEOD-7307
188 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-GEOD-5099, ... (24 experiments)

Factor Value U/D Experiments
NaOH
1
1
E-MEXP-2590
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-GEOD-5230
AMP
1
1
E-MEXP-2285
glucose
1
E-MEXP-941
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
eicosapentaenoic acid
1
E-MEXP-1389
29 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
46
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-4619, E-GEOD-1563, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-6207, E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-MEXP-1446, E-GEOD-10315, E-MEXP-1103, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-26, ... (39 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-22309, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.331 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM